Oric Pharmaceuticals ORIC
Oric Pharmaceuticals Q1 FY24: net loss $25.0M; diluted EPS −$0.37
- Form
- 10-Q
- Filed
- Period
- Importance
- Notable
- Accession
- 0000950170-24-053582
- Document
- 10-Q
- Exhibit 10.1
- Material contract
- Exhibit 10.2
- Material contract
Key figures from this report
These are the numbers Oric Pharmaceuticals reported for Q1 FY24, the quarter ended Mar 31, 2024, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.
- Net income−$25.0MNo year-earlier figure tagged10-Q income statement, on EDGAR
- Diluted EPS−$0.37No year-earlier figure tagged10-Q income statement, on EDGAR
- Cash and cash equivalents$56.4MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
- Cash from operations−$30.2MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- Geron GERN public float $861M, Jun 30, 2025
- Intellia Therapeutics NTLA public float $869M, Jun 30, 2025
- Wave Life Sciences WVE public float $851M, Jun 30, 2025
- CorMedix CRMD public float $910M, Jun 30, 2025
- Niagen Bioscience NAGE public float $814M, Jun 30, 2025